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Common and distinct patterns of grey-matter volume
alteration in major depression and bipolar disorder: evidence
from voxel-based meta-analysis
T Wise1, J Radua2,3,4, E Via5,6, N Cardoner5, O Abe7, TM Adams1, F Amico8, Y Cheng9, JH Cole10, C de Azevedo Marques Périco11,12,
DP Dickstein13, TFD Farrow14, T Frodl15,16, G Wagner17, IH Gotlib18, O Gruber19, BJ Ham20, DE Job21,22,23, MJ Kempton2,24, MJ Kim25,
PCMP Koolschijn26, GS Malhi27, D Mataix-Cols2,4, AM McIntosh28, AC Nugent29, JT O’Brien30,31, S Pezzoli2,32, ML Phillips33,
PS Sachdev34,35, G Salvadore36, S Selvaraj37, AC Stanﬁeld38, AJ Thomas30, MJ van Tol39, NJA van der Wee40,41, DJ Veltman42, AH Young1,
CH Fu1,43, AJ Cleare1 and D Arnone1
Finding robust brain substrates of mood disorders is an important target for research. The degree to which major depression (MDD)
and bipolar disorder (BD) are associated with common and/or distinct patterns of volumetric changes is nevertheless unclear.
Furthermore, the extant literature is heterogeneous with respect to the nature of these changes. We report a meta-analysis of voxel-
based morphometry (VBM) studies in MDD and BD. We identiﬁed studies published up to January 2015 that compared grey matter
in MDD (50 data sets including 4101 individuals) and BD (36 data sets including 2407 individuals) using whole-brain VBM. We used
statistical maps from the studies included where available and reported peak coordinates otherwise. Group comparisons and
conjunction analyses identiﬁed regions in which the disorders showed common and distinct patterns of volumetric alteration. Both
disorders were associated with lower grey-matter volume relative to healthy individuals in a number of areas. Conjunction analysis
showed smaller volumes in both disorders in clusters in the dorsomedial and ventromedial prefrontal cortex, including the anterior
cingulate cortex and bilateral insula. Group comparisons indicated that ﬁndings of smaller grey-matter volumes relative to controls
in the right dorsolateral prefrontal cortex and left hippocampus, along with cerebellar, temporal and parietal regions were more
substantial in major depression. These results suggest that MDD and BD are characterised by both common and distinct patterns of
grey-matter volume changes. This combination of differences and similarities has the potential to inform the development of
diagnostic biomarkers for these conditions.
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INTRODUCTION
Affective disorders such as major depression (MDD) and bipolar
disorder (BD) are serious conditions that signiﬁcantly affect quality
of life.1,2 In the absence of a deﬁnitive understanding of the
neuropathology underpinning these disorders, no clinical biomar-
kers are currently available to aid diagnosis and treatment.3–5
This is a particularly signiﬁcant issue given the frequency of
misdiagnosis and inappropriate treatment in affective disorders.6
As a result, biomarker discovery and optimisation are essential
steps for future progress.
Neuroimaging studies have identiﬁed a number of differences
between patients with affective disorders and healthy individuals
in brain volume, function, neurochemistry and connectivity in
key neurobiological circuits involved in mood regulation.3,7–11
Grey-matter volume changes in affective disorders have been well
documented in a number of cortical and subcortical structures
including prefrontal regions and the hippocampus.10,12–14 It is at
present unclear to what extent speciﬁc or common morphological
alterations occur in MDD and BDs given the paucity of direct
comparisons and inconsistencies in the available ﬁndings. The two
studies that have addressed this issue have identiﬁed differences
in prefrontal regions; however, the precise location differs in these
studies.15,16 Gaining a more detailed insight into the neuropatho-
logical relationship between these disorders is an essential step in
providing a more precise deﬁnition of candidate diagnostic
biomarkers at the brain level, which could improve current
classiﬁcations of affective disorders.
The aim of this meta-analysis was to use the largest database
of voxel-based morphometry (VBM) studies in affective disorders
to date by taking advantage of a thorough and detailed
meta-analytic technique to (1) identify morphometric changes in
MDD and BD compared with healthy controls and (2) compare
results across diagnostic groups to assess morphometric differ-
ences and similarities that may reﬂect common and/or distinct
neuropathological pathways in affective disorders. Most impor-
tantly, we adopt an improved meta-analytic technique with
increased sensitivity, speciﬁcity and reliability of the analyses, by
combining statistical maps from some of the original studies
with peak coordinates conventionally used in neuroimaging
meta-analyses.
MATERIALS AND METHODS
Literature searches
We searched Pubmed, Scopus and ScienceDirect for studies comparing
patients with MDD or BD with control groups published up to January
2015 using the following keywords: Magnetic resonance imaging OR MRI
AND depression OR BD OR mania OR mood disorders. Broad search terms
were used to minimise the likelihood of missing any relevant studies.
Reviews and meta-analyses were cross-referenced to identify studies that
were missed in the literature searches. Authors were contacted for
unpublished data including t-maps from the original studies. A systematic
approach compliant with PRISMA (Preferred Reporting Items for Systema-
tic Reviews and Meta-Analyses) guidelines17 was adopted.
Studies were excluded if: (1) they adopted neuroimaging techniques
other than MRI whole-brain VBM; (2) participants age was below 18 or
above 65 (to minimise the effect of neurodevelopment and neurodegen-
eration, respectively); (3) samples were confounded by any comorbid
neurological conditions; (4) t-maps were unavailable, consistent statistical
thresholds throughout the brain were not used or peak coordinates were
not reported; and (5) included ⩽ 10 patients. If the same patient group was
used in multiple studies, then only the study with the largest sample was
included. Conversely, when the same control group was used in several
subgroup comparisons, only a combined summary result was included in
the meta-analysis. For studies that used longitudinal treatment designs,
only baseline pre-treatment data were included.
Meta-analysis
Meta-analysis was performed using the anisotropic effect size version of
Seed-based DMapping (formerly Signed Differential Mapping, AES-SDM).18
This method has been described in detail elsewhere.19,20 In summary,
AES-SDM allows combination of peak coordinates and statistical para-
metric maps to create whole-brain effect size and variance maps, which are
then used to perform voxel-wise random effects meta-analyses. Although
meta-analyses based on peak coordinates alone are able to produce
reliable results, the addition of original statistical maps substantially
improves the sensitivity of the analyses.19 AES-SDM allows meta-analytic
summaries of grey-matter volumes within each disorder (for example,
MDD and BD vs healthy controls) and comparisons of abnormalities
between conditions (for example, MDD vs BD) based on the evaluation of
effect sizes. Finally, the multimodal analysis function of the AES-SDM
statistical package allows conjunction analyses to be performed, which
enabled us to identify regions where both patient groups show common
differences with respect to controls, while taking into account error in the
estimation of the magnitude of these differences.21
AES-SDM also allows heterogeneity to be systematically quantiﬁed in
a voxel-wise manner using the Q statistic. The overlap between signiﬁcant
areas of heterogeneity with areas of grey-matter differences was system-
atically investigated with separate simple meta-regressions using available
potential confounders where these were provided in a sufﬁcient
proportion of the included studies. Given the relatively small number of
studies, we set the cutoff for inclusion of potential confounders in meta-
regressions to ⩾ 20 studies in order to minimise the occurrence of false
positives.22 For MDD, we conducted meta-regressions with antidepressant
medication use, depression duration (from age of onset), depression
severity, mean patient age and sex. For BD, we used mood state,
depression duration, antipsychotic medication use, lithium use, mean
patient age and sex. We also examined effects of magnetic ﬁeld strength
and image smoothing level for both conditions. Studies that did not report
these measures were excluded from these analyses. To enable meta-
regressions to be conducted using a consistent measure of depression
severity, when studies reported Montgomery-Åsberg Depressing Rating
Scale23 scores, these were converted to Hamilton Depression Rating
Scale24 equivalents using the method devised by Heo et al.25 Group
differences in demographic and clinical variables were explored to
discover any potential confounders in group comparisons by using
standard meta-analytic tests weighted by sample size.
Signiﬁcant clusters were tested for publication bias using funnel plots
and Egger’s test on effect size estimates extracted from the cluster peak,
performed using the Metafor package26 for R (http://www.rproject.org).
Funnel plots of effect sizes in each cluster were also visually inspected to
ensure that results were robust. Finally, we assessed reliability of our meta-
analytic results with a jack-knife analysis, in which the meta-analysis is
rerun iteratively with each study left out in one iteration. This method
assesses the reliability of signiﬁcant results, on the assumption that reliable
results should be robust to the removal of individual studies, and should
therefore remain present in the majority of jack-knife iterations. Clusters
that were no longer signiﬁcant in the meta-analysis in 10% or more of the
iterations were rejected as we wished to include the most robust results,
which should be present in the majority of jack-knife iterations. In the text,
we only report clusters that met our criteria for robustness. We provide full
results and details regarding the meta-analysis method in Supplementary
methods.
RESULTS
Literature searches
Literature searches produced 14 951 results, of which 66 studies
met criteria for inclusion (Supplementary Figure 1). We also
identiﬁed ﬁve studies from previous meta-analyses and reviews. In
addition, we had access to statistical maps from two unpublished
studies, one in MDD and the other in BD. This resulted in a total of
73 studies included in the ﬁnal analysis. Details are presented in
Supplementary Tables 1 and 2.
Study characteristics
Major depression. We identiﬁed 41 studies that included 50 com-
parisons between patients and healthy controls (Supplementary
Table 1), of which statistical maps were available for 9. These
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studies included a total of 1736 patients and 2365 healthy
controls. Patients’ mean age was 38.5 years (s.d. = 9.7) and 38.7%
were male. The mean age of healthy control participants was 37.1
years (s.d. = 7.8), and 39.5% were male. In studies that provided
information on mood state, 1348 patients (94%) experienced
symptoms of depression at the time of scanning and 88 (6%) were
euthymic.
Demographic details were well reported across studies
(41 studies, 98%). With regard to clinical information, 11 studies
(26%) did not mention depression severity and 7 (17%) did not
refer to duration of illness.
Bipolar disorder. We identiﬁed 32 studies with 36 comparisons
between patients and healthy controls (Supplementary Table 2),
representing a total of 980 patients and 1427 controls. Original
statistical maps were available for six of these studies. Demo-
graphic details were reported in all studies. Availability of clinical
information was less consistent with 8 studies (25%) not reporting
the number of medicated patients, and 11 (34%) not providing
treatment details. With regard to symptoms, 9 (28%) studies did
not report the mood state, 17 studies (53%) did not provide a
measure of depressive symptoms, 16 studies (50%) did not
provide information on manic symptoms, 3 studies (9%) did
not provide a measure of illness duration and 18 (56%) did not
provide information on symptoms severity. The mean age of
patients was 37.6 years (s.d. = 4.4) and 44.1% were male. The mean
age of controls was 35.9 years (s.d. = 4.8), and 43.8% were male. In
relation to sub-types, 808 patients (82%) experienced type
I disorder, 91 (9%) were diagnosed as type II and for 81 patients
(8%) this information was not available. In the studies that
provided details of mood state, 438 patients (56%) were euthymic
at the time of scanning, 218 (28%) experienced symptoms of
depression, 118 (15%) were manic and 5 (1%) had mixed
symptoms.
MDD vs BD. Studies in MDD and BD included patients of similar
ages (omnibus test QM
(1) = 0.28, P= 0.60) and sex (QM
(1) = 0.95,
P= 0.33). Studies that reported duration of illness suggested
shorter total durations of illness in patients with MDD than BD
(weighted means 8.1 vs 12.5 years, QM
(1) = 9.51, P⩽ 0.002).
Predictably, more patients were in a depressive state at the time
of scanning in MDD studies (Χ2(1) = 22.30, Po0.001).
Meta-analysis
MDD vs healthy controls. Grey-matter volume differences in MDD
relative to healthy controls are shown in Table 1 and Figure 1a.
Clusters that did not meet criteria for robustness are shown in
Supplementary Table 3. The largest regions showing smaller grey-
matter volume in MDD were observed bilaterally in two clusters
comprising the insula, extending into the posterior part of the
inferior frontal gyrus and the anterior superior temporal gyrus. The
ventromedial prefrontal cortex showed lower volume in a large
area, which was predominantly inferior to the anterior cingulate
cortex. The posterior cingulate cortex and dorsal anterior cingulate
cortex also exhibited lower volumes. Several lateral prefrontal
regions showed smaller volumes, as did the left inferior parietal
gyrus and the right fusiform gyrus. Regions of lower volume were
also present in a number of subcortical and medial temporal
regions, including the left caudate, left hippocampus and left
parahippocampal gyrus.
Regions of greater volume relative to healthy controls were
observed in the bilateral superior occipital gyrus, extending into
the cuneus. Smaller clusters showing greater volume were found
in the right angular gyrus and right postcentral gyrus.
There was no evidence of publication bias or detectable small-
study effects in any cluster, as indicated by non-signiﬁcant Egger’s
tests of funnel plot asymmetry (all P-values 40.05). Details
of brain regions where signiﬁcant heterogeneity was measured
are provided in Supplementary Table 4. Signiﬁcant between-study
heterogeneity was explored with meta-regression analyses.
Results of these analyses indicated that studies with lower mean
depression severity found smaller grey-matter volumes relative to
controls in the left hippocampus (peak MNI =− 30, − 18, − 16,
Z= 2.73, Po0.001, 40 voxels), studies with a smaller proportion of
men found smaller grey-matter volume compared with controls in
bilateral ventromedial prefrontal cortex (peak MNI = 0, 38, − 18,
Z= 2.17, Po0.001, 359 voxels) and studies with older patients
found smaller volumes relative to controls in the left insula (peak
MNI =− 42, 16, − 2, Z=− 2.73, Po0.001, 49 voxels; Figures 1b–d).
We found no association with antidepressant medication use or
depression duration. When examining methodological variables,
Table 1. Clusters showing differences between MDD and controls that met our criteria for robustness
Peak MNI coordinate Z P Voxels Brodmann areas Regions
MDDoHealthy controls
− 42, 8, − 2 4.05 o0.001 3258 22, 38, 48 Left insula, inferior frontal gyrus, temporal pole, superior temporal gyrus
54, − 8, − 14 4.00 o0.001 1912 21, 22, 48 Right superior temporal gyrus, insula, inferior frontal gyrus
− 2, 40, − 18 3.40 o0.001 908 11 Left gyrus rectus, left medial orbitofrontal cortex, anterior cingulate cortex
0, 4, 42 3.34 o0.001 729 23, 24 Left middle cingulate cortex
− 10, 16, 6 3.53 o0.001 320 25 Left caudate nucleus
44, 48, − 8 3.12 o0.001 282 46, 47 Right middle frontal gyrus, orbital part
32, 42, 30 3.10 o0.001 144 46 Right middle frontal gyrus
− 28, 38, − 4 2.88 0.001 104 37 Left hippocampus, parahippocampal gyrus
− 40, − 54, 46 3.21 o0.001 93 40 Left inferior lobule
44, − 24, − 24 2.78 0.001 92 20 Right fusiform gyrus
4, 48, 22 2.80 0.001 53 32 Right anterior cingulate cortex
− 20, − 18, − 18 2.73 0.001 41 35 Left hippocampus, parahippocampal gyrus
− 4, 36, 40 2.67 0.001 36 32 Left superior medial frontal gyrus
MDD4Healthy controls
26, − 90, 14 − 1.81 ~ 0 731 17, 18 Right superior occipital gyrus, cuneus, middle occipital gyrus
− 10, − 96, 12 − 1.03 o0.001 733 17, 18 Left superior occipital gyrus
44, − 50, 26 − 1.33 o0.001 457 39 Right angular gyrus, middle temporal gyrus
52, − 4, 26 − 1.25 o0.001 161 4 Right postcentral gyrus
Abbreviation: MDD, major depressive disorder.
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Figure 1. (a) Results of major depressive disorder (MDD) meta-analysis. (b) Results of meta-regression with depression severity in MDD.
(c) Results of meta-regression with sex in MDD. (d) Results of meta-regression with patient age in MDD. (e) Results of bipolar disorder (BD)
meta-analysis. (f, g) Results of meta-regressions with age in BD. Orange represents lower volume in patients relative to controls or positive
relationships with regressors in meta-regressions, blue represents greater volume relative to controls or negative relationships with regressors.
In meta-regression plots, point size represents study weights. All images are shown in neurological convention; left on the image corresponds
to left in the brain. Effect sizes represent effect sizes at the peak of the cluster.
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studies using higher ﬁeld strength scanners showed smaller
volumes relative to controls in the left superior temporal gyrus
(peak MNI =− 50, 0, − 2, Z=− 2.53, Po0.001, 40 voxels), while the
opposite pattern was observed in the ventromedial prefrontal
cortex (peak MNI =− 2, 40, − 18, Z= 2.0, Po0.001, 187 voxels;
Supplementary Figure S2).
Bipolar disorder vs healthy controls. Patients with BD differed
from healthy controls in grey-matter volume in a number of
regions (Table 2 and Figure 1e). Clusters that did not meet criteria
for robustness are shown in Supplementary Table 5. The largest
areas showing lower grey-matter volume in patients relative to
controls were in the bilateral insula and superior temporal gyrus.
Another large cluster where smaller volumes were observed was
located in the medial prefrontal cortex, including the anterior
cingulate cortex. We also found small clusters showing greater
volume relative to controls in a number of areas, including a
number of cerebellar regions, bilateral middle frontal gyrus, right
middle and inferior temporal gyrus, and right middle occipital gyrus.
Regions in which BD showed greater volume relative to controls
included the inferior temporal gyrus and bilateral middle frontal
gyrus, as well as cerebellar and occipital areas.
Egger’s test of funnel plot asymmetry did not identify any
evidence of publication bias in any cluster (all P-values 40.05).
A number of regions showed signiﬁcant between-study hetero-
geneity (Supplementary Table 6). Meta-regression analyses
revealed that smaller volumes relative to controls were associated
with increasing age in the right middle temporal gyrus (Figure 1f,
peak MNI = 62, − 26, − 6, Z=− 3.07, Po0.001, 186 voxels). Higher
patient age was also associated with smaller volumes compared
with controls in the right caudate (Figure 1g, peak MNI = 8, 14, 12,
Z=− 2.60, Po0.001, 55 voxels). We found no signiﬁcant associa-
tions with mood state, antipsychotic medication use, lithium use,
sex or methodological variables.
MDD vs BD contrast. MDD differed from BD with respect to grey-
matter volume alterations in several regions (Table 3 and
Figure 2a). The most substantial difference involved the right
middle frontal gyrus, where smaller grey-matter volume relative to
controls was speciﬁc to MDD. A similar pattern was found in the
left hippocampus, right inferior temporal gyrus, left inferior
parietal lobule and right cerebellar vermis. There were no regions
in which the opposite pattern was observed.
Grey-matter volume alterations common to both disorders. Con-
junction analysis indicated that several regions in the bilateral
insula and in the dorsomedial and ventromedial prefrontal cortex,
including the pre-genual anterior cingulate cortex, showed smaller
volume compared with controls in both conditions (Figure 2b). No
regions showed greater volume compared with controls in both
conditions.
DISCUSSION
In this paper, we report ﬁndings from the largest meta-analysis
conducted to date of VBM studies in MDD and BD. We compared
results from these two conditions to identify common and distinct
patterns of grey-matter volume alterations. We showed that
the two conditions share similar patterns of lower volume in the
bilateral insula and medial prefrontal cortex, suggesting that there
Table 2. Clusters showing differences between BD and controls that met our criteria for robustness
Peak MNI coordinate Z P Voxels Brodmann areas Regions
BDoHealthy controls
− 4, 50, 4 4.04 o0.001 2210 10, 32 Bilateral anterior cingulate cortex, superior and ventral medial prefrontal cortex
54, 2, 0 3.95 o0.001 1898 21, 22, 38, 48 Right temporal pole, superior temporal gyrus, right insula
− 48, − 2, 0 3.06 o0.001 436 48 Left superior temporal gyrus, left insula, left rolandic operculum
BD4Healthy controls
40, − 44, − 12 − 1.56 o0.001 158 20, 21, 37 Right inferior temporal gyrus, middle temporal gyrus
24, − 36, − 38 − 1.59 o0.001 127 — Middle cerebellar peduncles
34, 26, 36 − 1.73 o0.001 84 46 Right middle frontal gyrus
− 32, 22, 38 − 1.41 0.001 71 46, 9 Left middle frontal gyrus
2, − 38, 6 − 1.54 0.001 54 — Cerebellar vermis
38, − 78, 8 − 1.35 0.001 15 19 Right middle occipital gyrus
Abbreviation: BD, bipolar disorder.
Table 3. Clusters showing similar and different grey-matter changes in MDD and BD
Peak MNI coordinate Z P Voxels Brodmann areas Regions
MDDoBD
34, 30, 40 − 2.46 o0.001 102 9, 46 Right middle frontal gyrus
− 26, − 38, − 2 − 2.47 o0.001 74 37 Left hippocampus, parahippocampal gyrus
42, − 26, − 22 − 2.33 o0.001 72 20 Right inferior temporal gyrus, fusiform gyrus
− 40, − 52, 44 − 2.25 o0.001 31 40 Left inferior parietal lobule
4, − 42, − 22 − 2.10 o0.001 14 — Right cerebellar vermis
Reductions in both MDD and BD
52, − 4, 2 4.97 o0.001 753 48 Right superior temporal gyrus, insula
− 42, 0, − 2 4.69 o0.001 377 38, 48 Left insula, superior temporal gyrus
− 4, 54, 18 4.28 0.001 115 10, 32 Left superior medial frontal gyrus, anterior cingulate cortex
4, 48, 22 4.20 0.001 50 32 Right anterior cingulate cortex
Abbreviations: BD, bipolar disorder; MDD, major depression disorder.
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may be an underlying pathological mechanism that is common
to affective disorders. A number of regions, including the left
hippocampus and right dorsolateral prefrontal cortex, differed
between conditions, indicating that these disorders may be
associated with spatially distinct patterns of pathophysiology.
Both conditions showed smaller grey-matter volumes relative to
control groups in the medial prefrontal systems, including the
anterior cingulate cortex. In MDD, this was predominantly located
in the most ventral and dorsal regions of the medial prefrontal
cortex, while in BD it was located in a large cluster anterior to the
genu of the corpus callosum, although this difference in location
was not statistically signiﬁcant. The conjunction analysis indicated
that the volumes of parts of the dorsomedial and ventromedial
prefrontal cortex were robustly lower in both conditions,
suggesting a consistent pattern across disorders. These regions
have been strongly implicated in mood regulation, and the
anterior cingulate cortex in particular has been shown to be
crucial in the regulation of affective states,27 and has been a target
of treatment with deep brain stimulation.28 Our results are
consistent with theories of mood dysregulation in affective
disorders that posit that dysfunction in regions such as the
medial prefrontal cortex leads to aberrant mood states.29 Further
work is necessary, however, to determine whether the structural
differences here are responsible for the altered function of these
networks.
We also found that bilateral insula volume was smaller in
patents in both conditions. This region is involved in a range
of functions, including affective processing and awareness
of bodily states,30,31 and atypical functioning of this region in
affective disorders has been found in functional neuroimaging
research.32,33 Notably, the insula has also been found by multiple
studies to predict treatment response in patients with
depression.34,35 Our ﬁnding of smaller insular volume in both
unipolar and bipolar subjects suggests that structural abnormal-
ities are present in the same areas in which altered function has
also been identiﬁed. The insula has been implicated in inter-
oceptive processing and general bodily awareness,36 and our
results may indicate that structural changes are associated with
altered interoceptive function in affective disorders;37,38 this is a
speculative interpretation, however, that requires direct testing.
Our comparison of the conditions revealed several areas of
smaller grey-matter volume that were signiﬁcantly greater in MDD
than in BD, most prominently in the left parahippocampal gyrus
and right dorsolateral prefrontal cortex, speciﬁcally the middle
frontal gyrus. Smaller volumes of the hippocampus and para-
hippocampal gyrus have been well documented in MDD, but have
Figure 2. (a) Regions showing differences between major depression disorder (MDD) and bipolar disorder (BD). Orange clusters represent
smaller grey-matter volume than controls, which is more substantial in MDD. (b) Results of the conjunction analysis showing regions with
similar volumetric alterations in both conditions. Here, orange represents regions showing signiﬁcantly lower volume in both conditions
relative to controls. IPL, inferior parietal lobule; ITG, inferior temporal gyrus; L, left; MFG, middle frontal gyrus; R, right. Effect sizes represent
effect sizes at the peak of the cluster.
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been reported less often in BD.12,14,39 Investigators have
suggested that this may be due to neuroprotective effects
of lithium, which counteracts volume loss in BD.40 We did not
ﬁnd any signiﬁcant heterogeneity in the hippocampus in BD,
suggesting that there was no variation in effect sizes due to
medication or other variables. It is important to note, however,
that we cannot exclude the possibility that this may be due to
reduced sensitivity of whole-brain VBM analyses in small regions
such as the hippocampus.41 Additionally, it is unlikely that this
difference between conditions can be explained by mood state in
MDD given that our meta-regressions showed that lower
depression severity in MDD was associated with smaller volumes
in this region. Alternatively, this may reﬂect sparing of the
hippocampus in BD due to protective factors in individuals
predisposed to the disorder.42
The dorsolateral prefrontal cortex has been linked to emotion
regulation,43 and the right dorsolateral prefrontal cortex speciﬁ-
cally has been associated with attentional control during
emotional tasks.44 Notably, repetitive transcranial magnetic
stimulation to this region has been reported to improve
symptoms in treatment-resistant depression,45 but results have
been less convincing in bipolar depression.46 Our ﬁndings add to
this literature by suggesting that volumetric alterations in this
region are speciﬁc to MDD, indicating that a differential pattern of
prefrontal grey-matter volume may potentially differentiate these
two disorders. It is important to mention that functional
alterations have been identiﬁed in the right dorsolateral prefrontal
cortex in BD.47 The relationship between functional and structural
alterations in these conditions remains unclear; and further
research is essential to understand potential functional and/or
structural disease-speciﬁc alterations within affective disorders in
the dorsolateral prefrontal cortex.
Our analyses within each condition also revealed a number
of areas of grey-matter changes that did not differ signiﬁcantly in
magnitude between disorders but that were not reliably smaller in
both disorders relative to controls. One notable difference in MDD
compared with controls involved the bilateral occipital cortex,
including primary visual and extrastriate cortices, where patients
showed a large area of greater volume relative to controls.
Although a number of studies have highlighted the possibility of
neurochemical48 and functional49,50 changes in these regions, we
believe this is the ﬁrst study to identify robust volumetric changes
in these locations. Given our efforts to ensure that our results were
reliable and robust, it is unlikely that this is simply a false positive
produced by the meta-analytic method, although we cannot
exclude the possibility that methodological issues in the original
studies may have caused spurious results. For example, it is
possible this could be an artefact caused by correction for
intracranial or total grey-matter volume combined with substan-
tially lower grey-matter volume in other areas, although this is a
speculative interpretation and would require conﬁrmation. The
potential role of occipital regions has rarely been investigated in
major depression, and further research is required to understand
whether these results are robust or whether they are a result
of the method used.
We found a number of regions that showed signiﬁcant
between-study heterogeneity, and we explored these using
meta-regressions. In MDD, studies with less severely depressed
patients showed smaller grey-matter volume in the hippocampus
than did investigations with more severe patients. This may
seem contradictory given that previous studies have showed the
opposite pattern.51,52 It is possible that it may be explained by the
use of medication. Treatment with selective serotonin reuptake
inhibitors is known to increase hippocampal volume,53,54 and
given this it is possible that more severely depressed patients had
received more extensive pharmacotherapy in the past, leading to
amelioration of pre-existing grey-matter volumetric abnormalities,
although we were unable to test this here due to historical
treatment data being unavailable in the original studies. However,
it is important to note that we only had access to information
regarding current depression severity, and it is possible that
lifetime depression severity, or chronic and treatment-resistant
symptom proﬁles, may be associated with different neuroanato-
mical proﬁles.
Our meta-regression analyses showed effects of demographic
variables in both conditions. In MDD, volume of the prefrontal
cortex was smaller in studies with fewer male patients. Anatomical
differences between sexes have been reported previously in
depression,55 although it is unclear what drives these differences.
In addition, we found smaller left insula volumes in studies
of MDD with older patients; in contrast, in BD studies with older
patients, we found smaller volumes in the right middle temporal
gyrus. Thus, there may be a different biological trajectory in
affective disorders in relation to these regions, although meta-
regressions should be interpreted with caution as they do not
directly test relations within samples.
This meta-analysis improves on previous studies in several ways.
First, the novel meta-analytic method used here allowed us to
identify common and distinct areas of grey-matter volume
alterations in affective disorders. Given the paucity of reports
comparing affective conditions directly, this approach enabled us
to identify volumetric aspects of common neuropathological
mechanisms, and potentially distinctive biomarkers. Second, we
were able to include a larger number of studies due to the rapid
growth of the ﬁeld and our access to as-yet unpublished data sets.
We are therefore able to provide the most conclusive picture
of volumetric changes currently available. Third, we included
a number of original statistical maps in our analyses. This
substantially improves the sensitivity and speciﬁcity of the
analysis, especially in cases in which individual studies have small
samples.19 Finally, the thorough and detailed approach used in
this work ensured that ﬁndings were robust and that hetero-
geneity was comprehensively explored. We found no evidence
of publication bias or small-study effects; nevertheless, it is
important to note that, given the small sample sizes of the
majority of the studies included in the analyses, we cannot
exclude the possibility of small-study bias.
Despite these strengths, we should also note several limitations
of this meta-analysis. First, we cannot determine causality from
these results due to the fact that all the included studies were
cross-sectional group comparisons, and it is not clear whether
these alterations are part of the pathogenesis of these disorders or
a consequence of the illness. It should be noted however that our
meta-regressions did not detect any effect of illness duration,
providing some evidence against the latter explanation. Second,
the effect size comparisons may not provide as accurate a picture
of group differences as studies directly comparing the two
conditions. To date, there have been very few VBM studies directly
comparing affective conditions15,16 making it difﬁcult to draw ﬁrm
conclusions concerning potential similarities and differences
between disorders. Hence, at present, the approach used in this
meta-analysis, with the limitation of indirectly comparing studies’
effect sizes, offers the most viable option to reach conclusions
generalisable beyond individual studies. Additionally, given the
inherent robustness of the meta-analytic method, our results
should provide a summary of the most reliable differences
between these disorders.
Third, the samples used in the studies differed between
disorders with respect to treatment status (for example, different
types of pharmacotherapy). Given that psychotropic medications
can have effects on brain structure,53 it is difﬁcult to be certain
that results are not entirely independent from medication status.
As a related point, the samples also differed in mood state and
illness duration. We found no evidence for effects of these
variables in meta-regressions within disorders, suggesting that this
is not likely to be a major concern. However, effects of mood state
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are particularly difﬁcult to rule out, given that a number of studies
included samples of mixed mood states and several did not
provide information on mood state. Consequently, it is not
possible to comment with certainty on the effect of mood state on
our results. Furthermore, we cannot exclude the possibility that
undiagnosed cases of BD presented as unipolar depression in the
original studies,6 and it is not possible to rule out the inﬂuence of
comorbidities such as anxiety disorders on the results as these
were not always well described in the original reports. Another
concern is that many of the retrieved studies included more
controls than patients. Although these unbalanced studies may
have theoretically biased results,56 it is not clear from the existing
literature that this is likely to affect our ﬁndings and conclusions.
Finally, we cannot be certain that these regions of common grey-
matter volume alterations are exclusive to affective disorders. A
recent meta-analysis by Goodkind et al.57 found that some of these
areas, such as the insula and dorsomedial prefrontal cortex, are lower
in volume across a range of psychiatric conditions including affective,
anxiety and psychotic disorders. This suggests that morphometric
grey-matter changes in these regions are not speciﬁcally pathogno-
monic to affective disorders, or are even a proxy for underlying
common disease processes or for risk factors such as life stressors or
effects of hormonal or inﬂammatory changes. Nevertheless, the
locations identiﬁed by Goodkind et al. differ from those reported in
this meta-analysis in their location and size. For example, the authors
demonstrated that the anterior left insula extending to the left
inferior frontal gyrus was affected across disorders. In our work, a
more posterior portion of the left insula was shown to be affected in
both MDD and BD, which has functional relevance given the
anterior-posterior division in insula function, with the posterior region
being speciﬁcally involved in interoception and bodily awareness.36
In conclusion, we have shown that MDD and BD show a
common pattern of lower grey-matter volume which predomi-
nantly includes the medial prefrontal and insular cortices. In
addition, the two conditions also show distinct patterns of volume
alterations in a number of other regions, most predominantly the
right dorsolateral prefrontal cortex and left hippocampus, which
are speciﬁc to MDD. There is signiﬁcant heterogeneity within
these results, but this could be partially explained by clinical and
demographic differences in clinical samples. These ﬁndings
suggest targets for neuroanatomical diagnostic biomarkers, but
also indicate that affective disorders are more morphologically
similar than they are different.
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